Abstract
In different human carcinoma types, mast cell infiltrate increases with respect to normal tissue and mast cell density correlates with a bad prognosis. To assess the role of mast cells in human thyroid cancer, we compared the density of tryptase-positive mast cells in 96 papillary thyroid carcinomas (PTCs) versus normal thyroid tissue from 14 healthy individuals. Mast cell density was higher in 95% of PTCs (n=91) than in control tissue. Mast cell infiltrate correlated with extrathyroidal extension (P=0.0005) of PTCs. We show that thyroid cancer cell-line-derived soluble factors induce mast cell activation and chemoattraction in vitro. Different mast cell lines (HMC-1 and LAD2) and primary human lung mast cells induced thyroid cancer cell invasive ability, survival and DNA synthesis in vitro. The latter effect was mainly mediated by three mast-cell-derived mediators: histamine, and chemokines CXCL1/GROα and CXCL10/IP10. We show that xenografts of thyroid carcinoma cells (8505-C) could recruit mast cells injected into the tail vein of mice. Co-injection of human mast cells accelerated the growth of thyroid cancer cell (8505-C) xenografts in athymic mice. This effect was mediated by increased tumor vascularization and proliferation, and was reverted by treating mice with sodium cromoglycate (Cromolyn), a specific mast cell inhibitor. In conclusion, our study data suggest that mast cells are recruited into thyroid carcinomas and promote proliferation, survival and invasive ability of cancer cells, thereby contributing to thyroid carcinoma growth and invasiveness.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Balkwill F . (2004). Cancer and the chemokine network. Nat Rev Cancer 4: 540–550.
Borrello MG, Degl'innocenti D, Pierotti MA . (2008). Inflammation and cancer: the oncogene-driven connection. Cancer Lett 67: 262–270.
Butterfield JH, Weiler D, Dewald G, Gleich GJ . (1988). Establishment of an immature mast cell line from a patient with mast cell leukaemia. Leuk Res 12: 345.
Castellone MD, Guarino V, De Falco V, Carlomagno F, Basolo F, Faviana P et al. (2004). Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas. Oncogene 23: 5958–5967.
Coussens LM, Raymond WW, Bergers G, Laig-Webster M, Behrendysen O, Werb Z et al. (1999). Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 13: 1382–1397.
Coussens LM, Werb Z . (2002). Inflammation and cancer. Nature 420: 860–867.
Curcio F, Ambesi-Impiombato FS, Perrella G, Coon HG . (1994). Long-term culture and functional characterization of follicular cells from adult normal human thyroids. Proc Natl Acad Sci USA 91: 9004–9008.
de la Torre NG, Buley I, Wass JA, Turner HE . (2006). Angiogenesis and lymphangiogenesis in thyroid proliferative lesions: relationship to type and tumour behaviour. Endocr Relat Cancer 13: 931–944.
de Paulis A, Prevete N, Fiorentino I, Rossi FW, Staibano S, Montuori N et al. (2006). Expression and functions of the vascular endothelial growth factors and their receptors in human basophils. J Immunol 177: 7322–7331.
Detoraki A, Staiano RI, Granata F, Giannattasio G, Prevete N, de Paulis A et al. (2009). Vascular endothelial growth factors synthesized by human lung mast cells exert angiogenic and proinflammatory effects. J Allergy Clin Immunol 123: 1142–1149.
Di Pasquale M, Rothstein JL, Palazzo JP . (2001). Pathologic features of Hashimoto's-associated papillary thyroid carcinoma. Hum Pathol 32: 24–30.
Gilfillan AM, Tzaczyk C . (2006). Integrated signalling pathways for mast-cell activation. Nat Rev Immunol 6: 218–230.
Huang B, Lei Z, Zhang GM, Li D, Song C, Li B et al. (2008). SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment. Blood 112: 1269–1279.
Jo YS, Li S, Song JH, Kwon KH, Lee JC, Rha SY et al. (2006). Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. J Clin Endocrinol Metab 91: 3667–3670.
Kalesnikoff J, Galli SJ . (2008). New developments in mast cell biology. Nat Immunol 9: 1215–1223.
Kirshenbaum AS, Aki C, Wu Y, Rottem M, Goff JP, Beaven MA et al. (2003). Characterization of novel stem cell factor responsive human mast cell lines LAD1 and 2 established from a patient with mast cell sarcoma/leukaemia; activation following aggregation of FcɛRI or FcγRI. Leuk Res 27: 677–682.
Klein M, Vignaud JM, Hennequin V, Toussaint B, Bresler L, Plénat F et al. (2001). Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. J Clin Endocrinol Metab 86: 656–658.
Kondo T, Ezzat S, Asa SL . (2006). Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 6: 292–306.
Mantovani A, Allavena P, Sica A, Balkwill F . (2008). Cancer-related inflammation. Nature 454: 436–444.
Marone G, Triggiani M, Genovese A, Paulis AD . (2005). Role of human mast cells and basophils in bronchial asthma. Adv Immunol 88: 97–160.
Melillo RM, Castellone MD, Guarino V, De Falco V, Cirafici AM, Salvatore G et al. (2005). The RET/PTC-RAS-BRAF linear signalling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest 115: 1068–1081.
Nakayama T, Yao L, Tosato G . (2004). Mast cell-derived angiopoietin-1 plays a critical role in the growth of plasma cell tumors. J Clin Invest 114: 1317–1325.
Parsons ME, Ganellin CR . (2006). Histamine and its receptors. Br J Pharmacol 147 (Suppl 1): S127–S135.
Pufnock JS, Rothstein JL . (2009). Oncoprotein signaling mediates tumor-specific inflammation and enhances tumor progression. J Immunol 182: 5498–5506.
Raman D, Baugher PJ, Thu YM, Richmond A . (2007). Role of chemokines in tumor growth. Cancer Lett 256: 137–165.
Rhoden KJ, Unger K, Salvatore G, Yilmaz Y, Vovk V, Chiappetta G et al. (2006). RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma. J Clin Endocrinol Metab 91: 2414–2423.
Rivera ES, Cricco GP, Engel NI, Fitzsimons CP, Martín GA, Bergoc RM . (2000). Histamine as an autocrine growth factor: an unusual role for a widespread mediator. Semin Cancer Biol 10: 15–23.
Ryder M, Ghossein RA, Ricarte-Filho JC, Knauf JA, Fagin JA . (2008). Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr Relat Cancer 15: 1069–1074.
Salvatore G, De Falco V, Salerno P, Nappi TC, Pepe S, Troncone G et al. (2006). BRAF is a therapeutic target in aggressive thyroid carcinoma. Clin Cancer Res 12: 1623–1629.
Scarpino S, Stoppacciaro A, Ballerini F, Marchesi M, Prat M, Stella MC et al. (2000). Papillary carcinoma of the thyroid: hepatocyte growth factor (HGF) stimulates tumor cells to release chemokines active in recruiting dendritic cells. Am J Pathol 156: 831–837.
Schneider U, Schwenk HU, Bornkamm G . (1977). Characterization of EBV-genome negative ‘null’ and ‘T’ cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non-Hodgkin lymphoma. Int J Cancer 19: 621–626.
Soucek L, Lawlor ER, Soto D, Shchors K, Swigart LB, Evan GI . (2007). Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med 13: 1211–1218.
Sumimoto H, Imabayashi F, Iwata T, Kawakami Y . (2006). The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med 203: 1651–1656.
Tan W, Martin D, Gutkind JS . (2006). The Galpha13-Rho signaling axis is required for SDF-1-induced migration through CXCR4. J Biol Chem 281: 39542–39549.
Theoharides TC, Conti P . (2004). Mast cells: the Jekyll and Hyde of tumor growth. Trends Immunol 25: 235–241.
Viglietto G, Maglione D, Rimbaldi M, Cerutti J, Romano A, Trapasso F et al. 1995. Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placental growth factor (PlGF) associated with malignancy in human thyroid tumors and cell lines. Oncogene 11: 1569–1579.
Visconti R, Cerutti J, Battista S, Fedele M, Trapasso F, Zeki K et al. 1997. Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NFkappaB p65 protein expression. Oncogene 15: 1987–1994.
Yang FC, Ingram DA, Chen S, Zhu Y, Yuan J, Li X et al. (2008). Nf1-dependent tumors require a microenvironment containing Nf1+/− and c-kit-dependent bone marrow. Cell 135: 437–448.
Welsh TJ, Green RH, Richardson D, Waller DA, O'Byrne KJ, Bradding P . (2005). Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J Clin Oncol 23: 8959–8967.
Acknowledgements
We would like to dedicate this paper to the memory of Professor Gaetano Salvatore, who continues to inspire our work. We are indebted to AS Kirshenbaum and JH Butterfield for the LAD2 and HMC-1 cell lines, respectively and to F Curcio for the P5 primary thyroid culture. We thank Mario Galgani and Salvatore De Simone for PBMC purification and 8505-C GFP-expressing cell sorting. We also thank Jean Ann Gilder for text editing. This study was supported by grants from the Associazione Italiana per la Ricerca sul Cancro (AIRC), the Istituto Superiore di Oncologia (ISO), the Project ‘Applicazioni Biotecnologiche dalle molecole all'uomo’ (MoMa), the EC Contract 03695 (GenRisk-T), the Project ‘Sviluppo di nuovi farmaci capaci alterare il microambiente tumorale e ripristinare la risposta immune anti-tumorale’ (ACC) and the Project ‘Molecular diagnostic and prognostic markers of thyroid neoplasis’ RF-CAM-353005 of the Health Ministry. VG was a fellow of the Fondazione Italiana per la Ricerca sul Cancro (FIRC).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Oncogene website
Rights and permissions
About this article
Cite this article
Melillo, R., Guarino, V., Avilla, E. et al. Mast cells have a protumorigenic role in human thyroid cancer. Oncogene 29, 6203–6215 (2010). https://doi.org/10.1038/onc.2010.348
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2010.348
Keywords
This article is cited by
-
Comprehensive analysis of BTNL9 as a prognostic biomarker correlated with immune infiltrations in thyroid cancer
BMC Medical Genomics (2023)
-
Exploiting innate immunity for cancer immunotherapy
Molecular Cancer (2023)
-
Mast cells inhibit colorectal cancer development by inducing ER stress through secreting Cystatin C
Oncogene (2023)
-
Mast Cells and Resistance to Immunotherapy in Cancer
Archivum Immunologiae et Therapiae Experimentalis (2023)
-
Sexually dimorphic effect of H-ferritin genetic manipulation on survival and tumor microenvironment in a mouse model of glioblastoma
Journal of Neuro-Oncology (2023)